FDA grants priority review to omalizumab for food allergies
If approved, monoclonal antibody omalizumab would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposure.
List view / Grid view
If approved, monoclonal antibody omalizumab would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposure.
Aimmune Therapeutics' PALFORZIA® has been approved by the European Commission as a treatment for peanut allergy.
Ten medicines have been recommended for marketing authorisation and 10 extensions of indication have been suggested by the EMA.